Altimetrik Completes Acquisition of SLK Software, Uniting Strengths to Unlock Value through AI-First and Digital Enablement
24.10.2025 18:57:00 CEST | Business Wire | Press Release
Altimetrik today announced the successful completion of its acquisition of SLK Software, marking a major milestone in the company’s journey to build a digital engineering powerhouse. As part of this transition, SLK Software will now operate under its new identity as “SLK, an Altimetrik company”.
The integration brings together Altimetrik’s AI-first, data-led innovation capabilities with SLK’s strength in Intelligent Enterprise, Digital Operations, Intelligent Infrastructure and Automation and Quality Engineering - spanning the entire digital enablement value chain from strategy and design to engineering and managed services. Anchored in a Practitioner-Led approach, the unified organization merges deep domain expertise with modern platforms and digital operating models to deliver bite-size, outcome-focused execution that accelerates time-to-value.
“I am thrilled to officially welcome the SLK team to Altimetrik, bringing together two organizations driven by purpose, innovation, and an unwavering commitment to help our customers lead with confidence in the era of intelligent business,” said Raj Sundaresan, CEO of Altimetrik. “Completing this acquisition marks a pivotal milestone that is about more than scale; it is about helping businesses grow responsibly in an AI-first world by reshaping how they harness AI to drive real, measurable impact.”
Altimetrik and SLK bring together a global team of over 10,000+ professionals across 17+ countries, operating more than 20+ engineering centres. The combined entity serves over 150 enterprise clients, including Fortune 500 leaders, offering the full continuum of AI-first enablement - spanning data, engineering, intelligent operations, and automation - empowering enterprises to move beyond experimentation to adoption and continuous value creation.
"Altimetrik and SLK joining forces marks a new era for enterprise technology," said Puneet Bhatia, Partner & Executive Chairman, India of TPG Capital Asia and Board Member at Altimetrik. "The unified company is poised to accelerate enterprise modernization and unlock transformative outcomes for our customers - a journey TPG is excited to champion alongside."
"This is a significant milestone in our investment journey, at a time when AI continues to act as a transformative source in today’s evolving business landscape, reshaping how companies operate, compete and grow,” said Vivek Mohan, Business Unit Partner at TPG Capital Asia and Board Member at Altimetrik. “With combined scale, AI expertise, and delivery excellence, Altimetrik and SLK will drive faster innovation, greater impact for clients, and unlock significant value creation."
Building on Altimetrik’s AI First approach, the launch of ALTI AI Adoption Lab™ and DomainForge.ai, Altimetrik and SLK will continue on that momentum, offering comprehensive capabilities across data, AI, product engineering and experience, platform modernization, analytics, DevSecOps, cybersecurity, intelligent infrastructure, and cloud operations, underpinned by strong technology partnerships. The combined organization also benefits from a stronger ecosystem of technology alliances, such as OpenAI, Amazon Web Services, Snowflake and Databricks.
Avendus Capital acted as the exclusive financial advisor to SLK Software. EY acted as the exclusive financial advisor to Altimetrik and TPG.
About Altimetrik
Altimetrik is an AI-first data and digital engineering company helping enterprises accelerate growth through an incremental, product-driven approach. As an official OpenAI services partner, our ALTI AI Adoption Lab™ and DomainForge.ai enable organizations to build and scale enterprise-grade AI solutions.
With 6,000+ practitioners worldwide and deep engineering DNA, we help businesses across BFSI, manufacturing, retail & CPG, automotive, healthcare, and life sciences modernize technology, launch new business models, and scale AI adoption, powered by data-led innovation, intelligent digital operations, and automation.
Recognized in the 2025 Constellation Research ShortList™ for Global AI Services and named a Major Contender in Everest Group’s PEAK Matrix® for BFSI and Life Sciences Digital Engineering, Altimetrik also ranks on Glassdoor’s Best Led Companies in 2025, delivering efficiency, visibility, and frictionless growth in the AI era. Learn more at altimetrik.com.
About SLK, an Altimetrik company
SLK, an Altimetrik company, is a global technology services provider focused on bringing AI, intelligent automation, and analytics together to create leading-edge technology solutions through a culture of partnership and continuous evolution. Following its acquisition by Altimetrik, the unified organization broadens its innovation ecosystem and global reach. This alignment combines SLK’s expertise in Intelligent Enterprise, Infrastructure Management, Automation and Quality Engineering, Digital Operations, and Industry-Focused Solutions with Altimetrik’s proficiency in Data and AI, Digital Business Enablement, Product and Platform Engineering, Cloud and Modernization, and Go-to-Market and Growth Execution. Together, they are poised to unlock value, accelerate modernization, and drive measurable AI-first innovation at scale.
For 25 years, the organization has been enabling enterprises across insurance, financial services, investment management, and manufacturing to reimagine their business and address both present and future needs. With this integration, the company will further expand into healthcare, life sciences, and retail, enhancing its ability to drive meaningful digital transformation. Recognized over the years by Great Place To Work®, Brandon Hall, Mercer | Mettl-HRedge Awards, and SHRM for its people practices and culture of excellence, the organization continues to constructively challenge the status quo to drive peak performance through disruptive technologies, applied innovation, and purposeful automation.
Find out how SLK helps leading organizations reimagine their business at www.slksoftware.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251024035009/en/
Contacts
Media
Altimetrik & SLK
Gurvinder Singh Sahni
GSahni@altimetrik.com
Matt McLoughlin
Gregory FCA
altimetrik@GregoryFCA.com
+1 610-228-2123
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom